- Microsize announces a long-term supply agreement with Cerus Corporation. The agreement includes a joint CAPEX investment to build additional dedicated manufacturing suite capacity.
- The partnership aims to provide high-throughput particle sizing services for the functional powders used in the INTERCEPT® Blood System for Plasma.
Microsize have announced the signing of a long-term supply agreement with Cerus Corporation to provide high-throughput particle sizing services for the functional powders used in the INTERCEPT® Blood System for Plasma. This pathogen inactivation technology is used by blood centres around the world to help safeguard the blood supply.
The new supply agreement includes a joint CAPEX investment to build additional dedicated manufacturing suite capacity in 2023 and to qualify a higher-throughput processing train. These investments will allow Cerus to support existing and future demand for INTERCEPT-treated blood components including plasma and cryoprecipitate.
TJ Higley, CEO of Microsize, commented, “We are excited to meet the challenge presented to us by Cerus, our long-standing partner and a global leader in pathogen inactivation technology, used for production of life-saving blood products.” He further added, “As Cerus grows, our new larger manufacturing suite, with increased automation and a digital batch record, will add efficiencies and reliability into the supply chain planning process.
Erik Bosman, Cerus’ vice president global supply chain, stated, “We are delighted to continue our relationship with Microsize with today’s news.” He expressed his gratitude to Microsize for helping them to execute on their mission to safeguard the global blood supply.
Overview of outsourcing trends 
